New drug trial aims to halt scarring in lungs
NCT ID NCT05828953
Summary
This study is testing whether an oral medication called anlotinib can slow the progression of scarring in the lungs for people with idiopathic pulmonary fibrosis (IPF) or similar progressive lung diseases. It will compare the drug against a placebo in about 30 participants over 52 weeks, measuring changes in lung function as the main goal. The trial aims to see if this cancer drug can be repurposed to help control this serious, chronic lung condition.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTERSTITIAL LUNG DISEASES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Wenzhou Medical University
RECRUITINGWenzhou, Zhejiang, 325000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.